SCHEMBL8305764

SCHEMBL8305764

Cc1ccc(N2CCOC2=O)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PARP1 P09874 1/20 0.40
IDH1 O75874 4/20 0.38
ADCY2 Q08462 1/20 0.38
SCN5A Q14524 1/20 0.38
SCN9A Q15858 1/20 0.38
PDE10A Q9Y233 1/20 0.37
PRKDC P78527 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CMA1 P23946 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CCR1 P32246 1/20 0.36
CCR2 P41597 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8306977 0.91 LMNA (0.39) LMNAALDH1A1HPGDSMN1; SMN2PARP1
SCHEMBL10192200 0.88 PARP1 (0.47) LMNAALDH1A1HPGDSMN1; SMN2PARP1
SCHEMBL5652989 0.83 MAPT (0.45) LMNAALDH1A1SMN1; SMN2PARP1IDH1
SCHEMBL22854543 0.81 NAAA (0.37) LMNAALDH1A1SMN1; SMN2PRKDCHSD17B10
SCHEMBL8306339 0.79 ALDH1A1 (0.45) LMNAALDH1A1HPGDSMN1; SMN2PRKDC
SCHEMBL2366406 0.78 HTT (0.56) LMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL2750210 0.77 MEN1 (0.56) LMNAALDH1A1SMN1; SMN2PARP1IDH1
SCHEMBL5654099 0.77 ALDH1A1 (0.57) LMNAALDH1A1SMN1; SMN2
SCHEMBL1845432 0.76 PARP1 (0.42) PARP1IDH1PDE10ACMA1
SCHEMBL10094732 0.75 P2RX7 (0.48) PARP1IDH1SCN9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
WO-2004082687-A1 LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS F12, F2, PEPD LMNA 2107/4885ALDH1A1 3204/4885HPGD 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.